Yair Lotan, M.D. Titles and Appointments Professor Endowed Title Jane and John Justin Distinguished Chair in Urology, in Honor of Claus G. Roehrborn, M.D. School Medical School Department Urology You have reached the Academic Profile. For more information on the doctor and patient care, please visit the clinical profile. Biography Yair Lotan, M.D., is a Professor of Urology, Chief of Urologic Oncology, and holder of the Jane and John Justin Distinguished Chair in Urology, in Honor of Claus G. Roehrborn, M.D. at UT Southwestern Medical Center. He is also Vice Chair for Clinical Affairs and director of the Clinical Research Office in the department of urology and the Medical Director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System. He was class valedictorian in high school and graduated with high honors from the University of Texas at Austin and Baylor College of Medicine in Houston. He trained in general surgery and urology at UT Southwestern and joined the faculty in 2003. A board-certified urologist, Dr. Lotan treats patients with bladder, prostate, kidney, ureteral, and testicular cancer. He also handles general urologic conditions, such as kidney stones and vasectomies. He is known nationally for his research on urine markers and molecular markers, which will help determine which patients are at higher risk for recurrent cancer. He is also involved in health economics research, which evaluates the cost-effectiveness of surgery and cancer prevention. He has participated in multiple collaborative studies involving early detection of bladder cancer. He is also a co-investigator on several NIH funded trials evaluating urine based tumor markers. Dr. Lotan is the primary investigator on several investigator-initiated studies evaluating the role of urine and tissue markers in management of bladder cancer. He is a member of several guidelines panels for evaluation of hematuria and management of muscle invasive bladder cancer. He has published over 600 peer reviewed papers and multiple reviews and book chapters. Dr. Lotan is the co-chair of the Harold C. Simmons Comprehensive Cancer Center disease oriented team for urologic cancers. He is also a member of UT Southwestern’s Clinical Research Planning Group and the Tissue Bank Steering Committee and Cancer Committee. He is a frequent guest speaker at medical conferences around the world and belongs to numerous professional organizations, including the American Urological Association, the Society of Urologic Oncology, and the Bladder Cancer Advocacy Network. He has published over 600 peer-reviewed research articles and several book chapters on urologic care and procedures, and he serves as editorial reviewer for medical periodicals such as the Journal of Urology, European Urology, Cancer, Urologic Oncology, and the British Journal of Urology International. Dr. Lotan was included in D Magazine's Best Doctors list for 2014, 2016, 20167, 2018, 2021, and 2022. Education Medical School Baylor College of Medicine (1997) Internship UT Southwestern Medical Center (1998), General Surgery Residency UT Southwestern Medical Center (1999), General Surgery Residency UT Southwestern Medical Center (2003), Urology Research Interest Biomarker research Decision analysis and outcomes research Robotic and laparoscopic surgery Urologic oncology Publications Featured Publications Survivin as a prognostic marker for urothelial carcinoma of the bladdre: a multicenter external validation study Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C. Bastian PJ, Nielsen ME, Muller SC, Sagalowsky AI, Lotan Y Clin Cancer Res November 2010 15(22) 7012-19 Bladder Cancer Screening in a High Risk Asymptomatic Population Using a Point of Care Urine Based Protein Tumor Marker Lotan Y, Elias K, Svatek RS, Bagrodia A, Nuss G, Moran B, Sagalowsky AI, J Urol May 2009 Prospective Evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial cardinoma of the bladder Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R J Urol June 2008 179(6) 2164-9 Lymphovascular Invasion is Independently Associated with Overall Survival, Cause-Specific Survival, and Locan and Distant Recurrence in Patients with Negative Lymph Nodes at Radical Cystectomy Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI J Clin Oncol. August 2005 August 22 Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, Lippman SM J Clin Oncol. March 2005 20;23(9) 1911-20 Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB, J Urol 2024 Oct 101097JU0000000000004278 A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Microhematuria Trial. Lotan Y, Daneshmand S, Shore N, Black P, Scarpato KR, Patel A, Lough T, Shoskes DA, Raman JD, J Urol 2024 May 101097JU0000000000003991 Epidemiology, Screening, and Prevention of Bladder Cancer. Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y, Eur Urol Oncol 2022 Dec 5 6 628-639 Patients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. Lotan Y, de Jong J, Liu VYT, Bismar TA, Boorjian SA, Huang HC, Davicioni E, Mian OY, Wright JL, Necchi A, Dall'Era MA, Kaimakliotis HZ, Black PC, Gibb EA, Boormans J, J Urol 2021 Oct 101097JU0000000000002261 Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence. Woldu SL, Souter L, Boorjian SA, Barocas DA, Lotan Y, Urol Oncol 2021 Apr Results 1-10 of 20 1 2 Next Last Honors & Awards Top Urology/Oncology Prostate Cancer USA (2024) AUA Honorary Member (2023) Bronze AwardBJUI International (2022) Castle Connolly Top Doctors (2022-2023) Best Doctors in DallasD Magazine (2021) BJU International Bronze AwardBJU International (2021) Reviewer of the MonthEuropean Urology, Your Platinum Journal (2020) Merit AwardAmerican Society of Clinical Oncology (ASCO) Cancer Foundation at the Genitourinary Cancers Symposium (2009) Best PosterSociety of Urologic Oncology Annual Meeting on Extraordinary Opportunities for Discovery National Cancer Institute (2008) Who’s Who in America (2008) Gerald P. Murphy Scholar AwardRecognition of Research in Prostate Cancer (2003) The Pfizer Scholars in Urology AwardUrology Pathology Course (2002) Professional Associations/Affiliations American Association for Cancer Research American Urologic Association National Urologic Ultrasound Faculty R.O.C.K. Society Society of Urologic Oncology/Society of Endourology
